GenMark Diagnostics to Present at the William Blair 33rd Annual Growth Stock Conference
GenMark Diagnostics to Present at the William Blair 33rdAnnual Growth Stock Conference
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NAS: GNMK) , a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the William Blair 33rd Annual Growth Stock Conference to be held at the Four Seasons Hotel in Chicago, IL, on Wednesday, June 12, 2013. Hany Massarany, President and Chief Executive Officer, will present at 4:00 p.m. Central Time (2:00 p.m. Pacific Time).
A live webcast and audio archive of the presentation will be available at http://ir.genmarkdx.com/events.cfm. A replay of the webcast will be available on the company's website for approximately 90 days.
GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Virus Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.
GenMark Diagnostics, Inc.
President, Chief Executive Officer
KEYWORDS: United States North America California Illinois
The article GenMark Diagnostics to Present at the William Blair 33rd Annual Growth Stock Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.